Disclosed are compounds having a compound of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, compositions thereof, and uses thereof for treating diseases mediated by TGF-beta receptor type 2 or a FLT3 mutated kinase.
本发明涉及具有以下化合物的化合物:公式I的化合物或其药学上可接受的盐,溶剂化物,互变异构体,同分异构体或其
氘代物,其组成物以及用于治疗由TGF-beta受体类型2或FLT3突变激酶介导的疾病的用途。